JPRN-jRCT2071230017招募中3 期
A multi-center, randomized, double-blind, placebocontrolled,parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography(CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events - VICTORION-PLAQUE
Hirano Takamitsu0 个研究点目标入组 5 人开始时间: 2023年5月28日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Fasting LDL-C local lab value at the Screening Visit of either i) >=100 mg/dL if on statin therapy but not on a maximally tolerated statin therapy; ii) >=150 mg/dL if statin naive and without documented statin intolerance; or iii) >=70 mg/dL if on a stable (>=4 weeks) dose of maximally tolerated statin therapy or if statin intolerant.
- •2.Participants may be pre-identified based on a CCTA or an invasive angiography that is performed as part of standard of care within 12 months prior to the participant's Screening Visit demonstrating:
- •Presence of coronary artery plaque with visual diameter stenosis <50% or
- •Coronary artery plaque with visual artery stenosis >50% but Fractional Flow Reserve (FFR) >0.8 by special wire measurement (CCTA or coronary angiography)
- •3.Fasting LDL-C local lab value >=70 mg/dL at the assessment performed during the Statin Optimization Period 3 Visit for participants going through the Statin Optimization Period.
- •4.Participants having Non-Obstructive Coronary Artery (NOCA) confirmed by CCTA with FFRct >0.8 and CT-adapted Leaman score >5 or coronary artery plaque with visual diameter stenosis >50% but with FFRct >0.8 and CT-adapted Leaman score >5 without previous cardiovascular events.
- •A standard of care CCTA may serve as the study baseline CCTA scan if it is performed within 3 months prior to the participant's Screening Visit and meets the inclusion criteria of FFRct >0.8 and CT-adapted Leaman score >5, which will be assessed by the Imaging Core Lab.
- •5.At the Baseline Visit, participants must be on a stable (>=4 weeks) dose of maximally tolerated statin therapy. Participants not on maximally tolerated statin therapy and who do not have documented statin intolerance can be screened but must enter the study via a Statin Optimization Period.
排除标准
- •1.Previous cardiovascular events history including myocardial infarction (MI), or prior coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)].
- •2.Planned revascularization (PCI) or (CABG).
- •3.Previous cerebrovascular events including:
- •Prior ischemic stroke thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus.
- •History of prior percutaneous or surgical carotid artery revascularization.
- •History of Peripheral Artery Disease (PAD):
- •Prior documentation of a resting ankle-brachial index <0.85.
- •History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery.
- •Prior non-traumatic amputation of a lower extremity due to peripheral artery disease.
- •4.Cardiac disorders, including any of the following:
- •Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, atrial fibrillation) within 3 months prior to randomization that is not controlled by medication or via ablation at the time of the Screening Visit.
- •Complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) prior to randomization.
- •5.NOCA participant who was prescreened by the Investigator with visual diameter stenosis >50% but FFR <0.8.
- •6.Contraindication for CCTA (e.g., allergic reactions to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA Visit as assessed by the Imaging Core Lab.
- •7.Pacemaker or implantable cardioverter-defibrillator (ICD) in situ.
- •8.Systolic Left Ventricle Ejection Fraction <30% at the Screening Visit.
- •9.Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization (assessed at the Screening Visit) despite antihypertensive therapy.
- •10.Heart failure New York Heart Association (NYHA) class III or class IV at the Screening Visit.
- •11.Renal insufficiency (eGFR <30 mL/min/1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the Screening Visit and at the Statin Optimization 3 Visit.
- •12.Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Screening Visit.
研究者
相似试验
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebocontrolled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload - TELESTOmyelodysplastic syndromes(low/int-1 risk)MedDRA version: 12.1Level: LLTClassification code 10019613Term: HemosiderosisEUCTR2009-012418-38-ITOVARTIS FARMA630
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebocontrolled, two-period cross-over study to assess the effect of 50 µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD - NDChronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: SOCClassification code 10038738EUCTR2010-018597-20-ITOVARTIS FARMA80
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebocontrolled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure - NDtype 2 diabetes and congestive heart failureMedDRA version: 9.1Level: LLTClassification code 10012647Term: Diabetic cardiomyopathyEUCTR2008-005012-41-ITOVARTIS FARMA246
招募中
3 期
A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patientsIgA kidney diseaseIgAN10029149NL-OMON56184ovartis3
进行中（未招募）
3 期
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsIgA NephropathyJPRN-jRCT2021200039Yamada Hiroyuki30